Use of the classic hallucinogen psilocybin for treatment of existential distress associated with cancer

Charles S. Grob, Anthony P. Bossis, Roland R Griffiths

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter reviews the potential of a treatment approach that uses psilocybin, a novel psychoactive drug, to ameliorate the psychospiritual distress and demoralization that often accompany a life-threatening cancer diagnosis. The focus of cutting-edge research beginning in the 1950s, the investigation of classic hallucinogens had a major impact on the evolving field of psychiatry, contributing to early discoveries of basic neurotransmitter systems and to significant developments in clinical psychopharmacology. While published reports of therapeutic breakthroughs with difficult-to-treat and refractory patient populations were initially met with mainstream professional enthusiasm, by the late 1960s and early 1970s the growing association of hallucinogens with widespread indiscriminate use led to the temporary abandonment of this promising psychiatric treatment model. After a hiatus lasting several decades, however, regulatory and scientific support has grown for the resumption of clinical research investigations exploring the safety and efficacy of a treatment model utilizing the classic hallucinogen, psilocybin, in a subject population that had previously demonstrated positive therapeutic response, patients with existential anxiety due to a life-threatening cancer diagnosis.

Original languageEnglish (US)
Title of host publicationPsychological Aspects of Cancer: A Guide to Emotional and Psychological Consequences of Cancer, Their Causes and Their Management
PublisherSpringer US
Pages291-308
Number of pages18
Volume9781461448662
ISBN (Print)9781461448662, 1461448654, 9781461448655
DOIs
StatePublished - Mar 1 2013

Fingerprint

Psilocybin
Hallucinogens
Psychiatry
Neoplasms
Psychopharmacology
Psychotropic Drugs
Therapeutics
Research
Population
Neurotransmitter Agents
Anxiety
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Grob, C. S., Bossis, A. P., & Griffiths, R. R. (2013). Use of the classic hallucinogen psilocybin for treatment of existential distress associated with cancer. In Psychological Aspects of Cancer: A Guide to Emotional and Psychological Consequences of Cancer, Their Causes and Their Management (Vol. 9781461448662, pp. 291-308). Springer US. https://doi.org/10.1007/978-1-4614-4866-2_17

Use of the classic hallucinogen psilocybin for treatment of existential distress associated with cancer. / Grob, Charles S.; Bossis, Anthony P.; Griffiths, Roland R.

Psychological Aspects of Cancer: A Guide to Emotional and Psychological Consequences of Cancer, Their Causes and Their Management. Vol. 9781461448662 Springer US, 2013. p. 291-308.

Research output: Chapter in Book/Report/Conference proceedingChapter

Grob, CS, Bossis, AP & Griffiths, RR 2013, Use of the classic hallucinogen psilocybin for treatment of existential distress associated with cancer. in Psychological Aspects of Cancer: A Guide to Emotional and Psychological Consequences of Cancer, Their Causes and Their Management. vol. 9781461448662, Springer US, pp. 291-308. https://doi.org/10.1007/978-1-4614-4866-2_17
Grob CS, Bossis AP, Griffiths RR. Use of the classic hallucinogen psilocybin for treatment of existential distress associated with cancer. In Psychological Aspects of Cancer: A Guide to Emotional and Psychological Consequences of Cancer, Their Causes and Their Management. Vol. 9781461448662. Springer US. 2013. p. 291-308 https://doi.org/10.1007/978-1-4614-4866-2_17
Grob, Charles S. ; Bossis, Anthony P. ; Griffiths, Roland R. / Use of the classic hallucinogen psilocybin for treatment of existential distress associated with cancer. Psychological Aspects of Cancer: A Guide to Emotional and Psychological Consequences of Cancer, Their Causes and Their Management. Vol. 9781461448662 Springer US, 2013. pp. 291-308
@inbook{3cad98db1e94451c93c2cbf20f86dfc0,
title = "Use of the classic hallucinogen psilocybin for treatment of existential distress associated with cancer",
abstract = "This chapter reviews the potential of a treatment approach that uses psilocybin, a novel psychoactive drug, to ameliorate the psychospiritual distress and demoralization that often accompany a life-threatening cancer diagnosis. The focus of cutting-edge research beginning in the 1950s, the investigation of classic hallucinogens had a major impact on the evolving field of psychiatry, contributing to early discoveries of basic neurotransmitter systems and to significant developments in clinical psychopharmacology. While published reports of therapeutic breakthroughs with difficult-to-treat and refractory patient populations were initially met with mainstream professional enthusiasm, by the late 1960s and early 1970s the growing association of hallucinogens with widespread indiscriminate use led to the temporary abandonment of this promising psychiatric treatment model. After a hiatus lasting several decades, however, regulatory and scientific support has grown for the resumption of clinical research investigations exploring the safety and efficacy of a treatment model utilizing the classic hallucinogen, psilocybin, in a subject population that had previously demonstrated positive therapeutic response, patients with existential anxiety due to a life-threatening cancer diagnosis.",
author = "Grob, {Charles S.} and Bossis, {Anthony P.} and Griffiths, {Roland R}",
year = "2013",
month = "3",
day = "1",
doi = "10.1007/978-1-4614-4866-2_17",
language = "English (US)",
isbn = "9781461448662",
volume = "9781461448662",
pages = "291--308",
booktitle = "Psychological Aspects of Cancer: A Guide to Emotional and Psychological Consequences of Cancer, Their Causes and Their Management",
publisher = "Springer US",

}

TY - CHAP

T1 - Use of the classic hallucinogen psilocybin for treatment of existential distress associated with cancer

AU - Grob, Charles S.

AU - Bossis, Anthony P.

AU - Griffiths, Roland R

PY - 2013/3/1

Y1 - 2013/3/1

N2 - This chapter reviews the potential of a treatment approach that uses psilocybin, a novel psychoactive drug, to ameliorate the psychospiritual distress and demoralization that often accompany a life-threatening cancer diagnosis. The focus of cutting-edge research beginning in the 1950s, the investigation of classic hallucinogens had a major impact on the evolving field of psychiatry, contributing to early discoveries of basic neurotransmitter systems and to significant developments in clinical psychopharmacology. While published reports of therapeutic breakthroughs with difficult-to-treat and refractory patient populations were initially met with mainstream professional enthusiasm, by the late 1960s and early 1970s the growing association of hallucinogens with widespread indiscriminate use led to the temporary abandonment of this promising psychiatric treatment model. After a hiatus lasting several decades, however, regulatory and scientific support has grown for the resumption of clinical research investigations exploring the safety and efficacy of a treatment model utilizing the classic hallucinogen, psilocybin, in a subject population that had previously demonstrated positive therapeutic response, patients with existential anxiety due to a life-threatening cancer diagnosis.

AB - This chapter reviews the potential of a treatment approach that uses psilocybin, a novel psychoactive drug, to ameliorate the psychospiritual distress and demoralization that often accompany a life-threatening cancer diagnosis. The focus of cutting-edge research beginning in the 1950s, the investigation of classic hallucinogens had a major impact on the evolving field of psychiatry, contributing to early discoveries of basic neurotransmitter systems and to significant developments in clinical psychopharmacology. While published reports of therapeutic breakthroughs with difficult-to-treat and refractory patient populations were initially met with mainstream professional enthusiasm, by the late 1960s and early 1970s the growing association of hallucinogens with widespread indiscriminate use led to the temporary abandonment of this promising psychiatric treatment model. After a hiatus lasting several decades, however, regulatory and scientific support has grown for the resumption of clinical research investigations exploring the safety and efficacy of a treatment model utilizing the classic hallucinogen, psilocybin, in a subject population that had previously demonstrated positive therapeutic response, patients with existential anxiety due to a life-threatening cancer diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=84924860824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924860824&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-4866-2_17

DO - 10.1007/978-1-4614-4866-2_17

M3 - Chapter

SN - 9781461448662

SN - 1461448654

SN - 9781461448655

VL - 9781461448662

SP - 291

EP - 308

BT - Psychological Aspects of Cancer: A Guide to Emotional and Psychological Consequences of Cancer, Their Causes and Their Management

PB - Springer US

ER -